Protective effects of aliskiren and valsartan in mice with diabetic nephropathy

Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes

(2012) Hans-Henrik Parving et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combination of direct renin inhibition with angiotensin type 1 receptor blockade improves aldosterone but does not improve kidney injury in the transgenic Ren2 rat

(2012) Adam Whaley-Connell et al.   REGULATORY PEPTIDES

The Renin-Angiotensin-Aldosterone System in Podocytes

(2012) Dirk Oliver Wennmann et al.   SEMINARS IN NEPHROLOGY

Aliskiren in Combination with Losartan Reduces Albuminuria Independent of Baseline Blood Pressure in Patients with Type 2 Diabetes and Nephropathy

(2011) F. Persson et al.   Clinical Journal of the American Society of Nephrology

Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy

(2011) Frederik Persson et al.   JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM

Unknown

(2011) Chun Liu et al.   MOLECULAR MEDICINE

Aliskiren improves insulin resistance and ameliorates diabetic vascular complications in db/db mice

(2011) Young Sun Kang et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Induction of Diabetes in Aged C57B6 Mice Results in Severe Nephropathy

(2010) Jin Wu et al.   AMERICAN JOURNAL OF PATHOLOGY

Improved Lipid and Glucose Metabolism in Transgenic Rats With Increased Circulating Angiotensin-(1-7)

(2010) Sérgio Henrique S. Santos et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Angiotensin-converting enzyme 2 is a key modulator of the renin–angiotensin system in cardiovascular and renal disease

(2010) Chris Tikellis et al.   CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model

(2010) X. X. Wang et al.   DIABETES

Impact of Baseline Renal Function on the Efficacy and Safety of Aliskiren Added to Losartan in Patients With Type 2 Diabetes and Nephropathy

(2010) F. Persson et al.   DIABETES CARE

Direct renin inhibition improved insulin resistance and adipose tissue dysfunction in type 2 diabetic KK-Ay mice

(2010) Masaru Iwai et al.   JOURNAL OF HYPERTENSION

Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice

(2010) Yi-Fei Dong et al.   JOURNAL OF HYPERTENSION

Nuclear hormone receptors in diabetic nephropathy

(2010) Xiaoxin X. Wang et al.   Nature Reviews Nephrology

Lipotoxicity in macrophages: evidence from diseases associated with the metabolic syndrome

(2009) Xavier Prieur et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

New aspects of the renin–angiotensin system: angiotensin-converting enzyme 2 – a potential target for treatment of hypertension and diabetic nephropathy

(2009) Daniel Batlle et al.   CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

Aliskiren: a novel renoprotective agent or simply an alternative to ACE inhibitors?

(2009) Kathryn J. Wiggins et al.   KIDNEY INTERNATIONAL

An update on the lipid nephrotoxicity hypothesis

(2009) Xiong Z. Ruan et al.   Nature Reviews Nephrology

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design

(2009) H.-H. Parving et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Apoptosis induced by endoplasmic reticulum stress involved in diabetic kidney disease

(2008) Guanghui Liu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Proteinuria and Hyperglycemia Induce Endoplasmic Reticulum Stress

(2008) M. T. Lindenmeyer et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Proteinuria in diabetic kidney disease: A mechanistic viewpoint

(2008) J.A. Jefferson et al.   KIDNEY INTERNATIONAL

Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy

(2008) Hans-Henrik Parving et al.   NEW ENGLAND JOURNAL OF MEDICINE